FTX-6274 / Fulcrum Therap - LARVOL DELTA

FTX-6274, an EED inhibitor, demonstrates robust efficacy in castration resistant prostate cancer (CRPC) (ESMO 2025) - "In vivo mouse xenograft studies in AR positive prostate cancer models revealed that FTX-6274 demonstrated significant tumor growth inhibition compared to the EZH2 inhibitor mevrometostat. Further, our results indicate that FTX-6274 may have the potential to enhance efficacy as a combination therapy with ARPI in CRPC. Legal entity responsible for the study Fulcrum Therapeutics, Inc."

Clinical • Castration-Resistant Prostate Cancer • Diffuse Large B Cell Lymphoma • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 (StockTitan.net) - "Preclinical data of FTX-6274 suggests potential for the treatment of castration resistant prostate cancer"

Preclinical • Castration-Resistant Prostate Cancer